NLRP3 and cystic fibrosis: The pathogenic NLRP3 activity in CF may be reduced using the IL-1 antagonist receptor Anakinra, that by blocking the biological IL-1α and IL-1β activity ameliorated tissue damage and inflammation against P. aeruginosa in CF, with positive repercussion also on autophagy and neutrophils infiltration (Iannitti et al., 2016).